Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X:
“A phase II study (n=25) reports an 80% pCR rate for stage I NSCLC treated with SBRT plus 3 cycles of pembrolizumab. I’m curious whether the time to surgery (~12 weeks) explains the higher pCR rate compared to MISSILE (10 weeks), and whether the one tumor with 0% response harbored a KEAP1 mutation.”
Title: Pathologic Responses to Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early Stage NSCLC: A Phase 2 Study
Authors: Gustavo Schvartsman, Yasmin M. Amirato, Frederico Monfardini, Gustavo Prado dos Santos, Diogo B. D. Gomes, Ludmila de O. M. Koch, Benoit J. Bibas, Oswaldo Gomes Jr., Paulo V. Campregher, Patrícia Severino, Luciana C. Marti, Vitor R. Paes, Laura Leaden, Rodrigo C. Chate, Jose M. Ribas, Victor A. R. Sousa, Patrícia Taranto, Fernando Moura, Ricardo M. Terra, Ana Carolina Pires de Rezende, Marcos N. Samano
Read the Full Article.
Other articles featuring Drew Moghanaki on OncoDaily.
